江苏华兰药用新材料股份有限公司 信息披露暂缓与豁免业务管理制度 第一章 总 则 第一条 为加强江苏华兰药用新材料股份有限公司（以下简称"公司"）信 息披露暂缓与豁免行为，确保公司及相关信息披露义务人（以下简称"信息披 露义务人"）依法合规地履行信息披露义务，根据《中华人民共和国证券法》 《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 （以下简称"《规范运作指引》"）等法律、法规、部门规章、规范性文件， 及《江苏华兰药用新材料股份有限公司章程》（以下简称"《公司章 程》"）、《江苏华兰药用新材料股份有限公司信息披露事务管理制度》等规 定，结合公司实际情况，制定本制度。 第二条 公司和信息披露义务人按照《上市规则》《规范运作指引》及其他 相关法律、法规、规范性文件的规定，办理信息披露暂缓、豁免业务的，适用 本制度。 第三条 公司应审慎判断应披露的信息是否存在《上市规则》《规范运作指 引》及深圳证券交易所其他相关业务规则中规定的可暂缓、豁免披露情形，并 采取有效措施防止暂缓或豁免披露的信息泄露，接受深圳证券交易所对信息披 露 ...

证券代码：301093 证券简称：华兰股份 公告编号：2023-064 江苏华兰药用新材料股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2023 年 1 月 6 日 召开第五届董事会第九次会议、第五届监事会第八次会议，分别审议通过了《关 于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司及子公司 使用不超过人民币 175,000 万元的闲置募集资金（含超募资金，下同）和自有资 金进行现金管理，其中募集资金不超过 145,000 万元、自有资金不超过 30,000 万 元。具体内容详见公司 2023 年 1 月 6 日于指定信息披露媒体和巨潮资讯网 （www.cninfo.com.cn）上披露的《关于使用部分闲置募集资金和自有资金进行现 金管理的公告》（公告编号：2023-004）。 一、 本次使用部分闲置募集资金进行现金管理到期赎回情况如下： | | | | | | | 金额单位：万元 | | ...

证券代码：301093 证券简称：华兰股份 公告编号：2023-063 江苏华兰药用新材料股份有限公司 关于受让股权投资基金份额暨对外投资的进展公告（四） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 对外投资概述 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）于 2022 年 3 月 22 日召开了第五届董事会第一次会议，审议通过了《关于受让股权 投资基金份额暨对外投资的议案》，同意公司与江阴临港创业投资有限公司（以 下简称"临港创投"）、无锡国联金投启源私募基金管理有限公司签署《财产份 额转让协议》以及《江阴启泰产业投资基金合伙企业（有限合伙）有限合伙协 议》（以下简称"原合伙协议"）。公司拟以自有资金 3,000 万元人民币受让江阴 临港创业投资有限公司持有的江阴启泰产业投资基金合伙企业（有限合伙）（以 下简称"启泰基金"或"合伙企业"）5.15%的份额。本次交易完成后，公司成 为启泰基金的有限合伙人。启泰基金已在中国证券投资基金业协会私募登记备 案系统完成备案。具体内容详见公司分别于 2022 年 3 月 23 日、2022 ...

Group 1: Company Overview and Market Position - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. is a leading enterprise in the domestic pharmaceutical rubber stopper industry [2] - The company has a market share that is difficult to quantify due to a lack of authoritative statistics, but it competes with major players like Huaqing Technology and Shengzhou Pharmaceutical [3] - The global pharmaceutical rubber stopper market is highly concentrated, with West Pharmaceutical Services holding over 50% market share [3] Group 2: Financial Performance and Projections - In 2022, the company's gross profit margin was 43.63%, down from 55.12% in the previous year, primarily due to changes in product structure and increased production costs [5] - The company plans to distribute a cash dividend of 3 CNY per 10 shares, totaling approximately 40.74 million CNY [3] - The weighted average return on equity for 2022 was only 3.89%, impacted by a significant increase in net assets following the company's IPO [4] Group 3: Strategic Initiatives and Future Plans - The company is focusing on expanding production capacity through automation and smart factory projects, as well as increasing the output of pre-filled medical packaging materials [3] - Hualan is actively exploring overseas markets, with a 21.59% increase in international revenue in 2022, and plans to deploy sales representatives in Southeast Asia, Africa, and South America [3] - The company is considering mergers and acquisitions that align with its core business and can provide strategic support [4] Group 4: Challenges and Risk Management - The company faces risks related to the supply of key raw materials, which are primarily imported from countries like the USA and Japan [6] - To mitigate these risks, Hualan is exploring domestic alternatives and optimizing procurement channels [6] - The company has experienced delays in fundraising project implementation due to macroeconomic factors and supply chain constraints [6]

证券代码：301093 证券简称：华兰股份 公告编号：2023-040 江苏华兰药用新材料股份有限公司 普遍关注的问题进行回答。欢迎广大投资者积极参与。 特此公告。 江苏华兰药用新材料股份有限公司董事会 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）已于 2023 年 04 月 24 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定 于 2023 年 05 月 17 日（星期三）15:00-16:30 在"价值在线"（www.ir-online.cn） 举办 2022 年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投资者的 意见和建议。 届时出席本次说明会的人员有：公司董事长、总经理华一敏先生，独立董事 柳丹先生，保荐代表人邹晓东先生，副总经理、财务总监徐立中先生，副总经理、 董事会秘书刘雪女士。本次年度业绩说明会将采用网络互动方式举行，投资者通 过访问网址（h ...

Financial Performance - The company's revenue for Q1 2023 was CNY 156,340,882.84, representing a 19.42% increase compared to CNY 130,918,431.95 in the same period last year[4] - Net profit attributable to shareholders was CNY 33,252,865.25, up 6.70% from CNY 31,165,938.51 year-on-year[4] - The net cash flow from operating activities increased by 61.31% to CNY 37,293,788.25, compared to CNY 23,119,604.44 in the previous year[4] - The company reported a significant increase in investment income, which rose by 296.11% to CNY 6,984,776.55 from CNY 1,763,333.33 in the same period last year[10] - The company received government subsidies amounting to CNY 6,753,858.37, an increase of 1101.82% compared to CNY 561,970.31 in the previous year[10] - The company's basic earnings per share increased by 6.49% to CNY 0.246 from CNY 0.231 year-on-year[4] - The company reported a total profit of CNY 38,888,190.97 for Q1 2023, an increase of 6.1% from CNY 36,559,342.51 in Q1 2022[22] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.246, up from CNY 0.231 in the same period last year, representing a growth of 6.5%[23] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,636,844,441.83, a 2.20% increase from CNY 2,580,138,713.97 at the end of the previous year[4] - The company's total current assets at the end of Q1 2023 amounted to ¥2,068,453,656.90, slightly down from ¥2,080,554,351.93 at the beginning of the year[19] - Non-current assets increased to ¥568,390,784.93 from ¥499,584,362.04, representing a growth of 13.8%[19] - Total liabilities as of Q1 2023 were ¥184,999,638.21, compared to ¥164,210,450.60 at the start of the year, indicating an increase of 12.5%[20] - The company's retained earnings rose to ¥408,515,243.41 from ¥375,262,378.16, an increase of 8.9%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,089[12] - Jiangyin Hualan Electromechanical Technology Co., Ltd. holds 20.83% of shares, totaling 28,280,000 shares[12] - Huaxia Life Insurance Co., Ltd. holds 16.17% of shares, totaling 21,956,522 shares[12] - The top ten shareholders include individuals and entities with significant stakes, such as a natural person holding 5.47% (7,426,249 shares)[12] - The total number of restricted shares at the beginning of the period was 38,227,846, with an increase of 1,120,000 shares, bringing the total to 39,347,846[16] - Jiangyin Hualan Electromechanical Technology Co., Ltd. has 28,280,000 restricted shares, which are subject to a lock-up period until May 5, 2025[15] - The company has a significant number of shares under incentive plans, with various individuals holding restricted shares that will unlock in 2023 and 2025[16] - The company has not reported any significant changes in the number of preferred shareholders[14] Operational Insights - Total operating revenue for Q1 2023 reached ¥156,340,882.84, an increase of 19.4% compared to ¥130,918,431.95 in the same period last year[21] - Total operating costs for Q1 2023 were ¥133,470,456.13, up from ¥106,137,828.50, reflecting a year-over-year increase of 25.7%[21] - The cash and cash equivalents at the end of Q1 2023 were ¥134,188,316.72, down from ¥145,509,012.15 at the beginning of the year[19] - Inventory levels increased to ¥129,818,169.16 from ¥119,237,518.81, reflecting an increase of 8.3%[19] - Operating cash flow for Q1 2023 was CNY 37,293,788.25, significantly higher than CNY 23,119,604.44 in Q1 2022, marking an increase of 61.4%[24] - Investment activities resulted in a net cash outflow of CNY 67,068,869.87 in Q1 2023, an improvement from a net outflow of CNY 1,727,470,246.32 in Q1 2022[24] Other Information - The report indicates that there are no other important matters to disclose at this time[17] - The financial statements for the first quarter of 2023 are prepared and available for review[17] - The company experienced a financial expense of CNY 1,104,525.55 in Q1 2023, compared to a financial income of CNY 3,457,426.00 in Q1 2022[22] - Research and development expenses for Q1 2023 were CNY 8,655,646.30, slightly down from CNY 9,236,551.11 in Q1 2022[22] - The company did not report any significant new product launches or market expansions during this quarter[22]

Financial Performance - The company's operating revenue for 2022 was ¥584,137,522.12, a decrease of 28.84% compared to ¥820,866,851.98 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥93,751,536.87, down 56.60% from ¥216,019,162.93 in 2021[25]. - The net profit after deducting non-recurring gains and losses was ¥64,289,422.91, a decline of 69.95% from ¥213,952,774.28 in the previous year[25]. - The basic earnings per share for 2022 was ¥0.696, a decrease of 65.65% compared to ¥2.026 in 2021[25]. - The total assets at the end of 2022 were ¥2,580,138,713.97, a decrease of 2.01% from ¥2,632,955,496.82 at the end of 2021[25]. - The company reported a net cash flow from operating activities of ¥94,883,342.97, down 56.18% from ¥216,537,730.22 in 2021[25]. - The gross profit margin for the reporting period was 43.63%, a decline of 11.49% compared to the previous year[64]. - The company achieved revenue of 584.14 million yuan, a year-on-year decrease of 28.84%[63]. - The net profit attributable to shareholders was 93.75 million yuan, down 56.60% year-on-year[63]. - The company reported a significant drop in sales volume of pharmaceutical packaging products by 30.60%, primarily due to a sharp decline in orders for vaccine stoppers[70]. Dividend Distribution - The company reported a profit distribution plan to distribute a cash dividend of 3 RMB per 10 shares (including tax) to all shareholders, based on 135,786,667 shares[7]. - The company distributed a cash dividend of 3 yuan per 10 shares, totaling 40,736,000.10 yuan, which represents 100% of the total profit distribution[172]. - The company has no plans for stock dividends or capital reserve transfers, focusing solely on cash dividends for the reporting period[172]. Market and Industry Outlook - The company operates in the pharmaceutical packaging materials industry, which is expected to grow due to factors such as economic growth and an aging population[34]. - The market for pharmaceutical rubber stoppers is large and continues to grow, with a focus on increasing the penetration of film-coated stoppers[34]. - The company is a leading player in the domestic pharmaceutical rubber stopper industry, with significant competition from firms like Huachang Technology and Shandong Pharmaceutical Glass[35]. - The global pharmaceutical rubber stopper market is currently dominated by four companies, with West Pharmaceutical holding over 50% market share, indicating significant growth potential for the company[109]. - The company is committed to developing high-quality pharmaceutical rubber stoppers to capture more market share in the mid-to-high-end market segment[105]. Strategic Initiatives - The company is investing in automation and intelligent factory transformation projects to enhance production capacity for pre-filled medical packaging materials[18]. - The company is expanding its production capacity for medical packaging materials using over-raised funds, indicating a focus on market expansion[18]. - The company plans to enhance automation and smart factory upgrades, as well as expand the production capacity of pre-filled medical packaging materials[35]. - The company aims to achieve dynamic sealing in its new products to mitigate leakage risks during use[81]. - The company is actively seeking consolidation opportunities in the pharmaceutical packaging industry to expand its strategic layout through acquisitions and partnerships[112]. Research and Development - Research and development investment for the year was 36.69 million yuan, a decrease of 12.82% from the previous year[65]. - The company is developing a pre-filled catheter flushing solution to reduce external contamination and improve product competitiveness[81]. - The company is focusing on the domestic market for pre-filled packaging materials, aiming to reduce reliance on foreign products and enhance local production capabilities[82]. - The company is committed to increasing R&D investment to maintain its competitive edge in the pharmaceutical rubber stopper industry[117]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency[148]. Governance and Compliance - The company has established a robust internal control system to enhance decision-making and operational transparency[113]. - The company held four shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[123]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards[125]. - The company has established an independent financial accounting system and does not share bank accounts with controlling shareholders[135]. - The company has implemented a series of internal control measures, including management rules and procedures, to ensure compliance and operational integrity[177]. Social Responsibility and Sustainability - The company has committed a total of ¥2,659,146.94 to social welfare and charity initiatives during the reporting period, supporting various educational and community projects[187]. - The company emphasizes environmental protection and sustainable development, promoting advanced and energy-efficient technologies[186]. - The company actively engages in social responsibility, ensuring legal compliance and maintaining good relationships with stakeholders[183]. - The company is committed to sustainability and is integrating eco-friendly practices into its production processes, aligning with global trends[143]. Future Projections - Future plans and forward-looking statements in the report do not constitute a substantive commitment to investors, highlighting the need for risk awareness[6]. - The company plans to enhance its digital factory capabilities with a top-level design contract worth 18.99 million yuan with Huawei[57]. - The company has set ambitious performance guidance for the upcoming fiscal year, projecting a revenue growth rate of over 15%[143]. - The company plans to launch three new products in 2023, focusing on innovative drug delivery systems[193]. - Future outlook includes a projected revenue growth of 10-15% for 2023, driven by increased market demand and new product launches[195].

Group 1: Company Overview - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. is involved in the production of medical packaging materials and has a significant industry position [2]. - The company has a development strategy focused on automation and intelligent factory transformation [2]. Group 2: Recent Developments - The company announced a stock incentive plan for 2022-2025, with high assessment indicators based on production capacity projects [2]. - As of the end of Q3 2022, COVID-19 related orders accounted for a small percentage of the company's total revenue [3]. Group 3: Shareholder Information - In November 2022, the company released 63,781,107 shares, with major shareholder commitments to maintain a minimum selling price [3]. - Some shareholders have already reduced their holdings through block trades and centralized bidding [3]. Group 4: Fundraising and Financial Planning - The total amount raised from the IPO was RMB 1.955 billion, with a net amount of RMB 1.804 billion after expenses [3]. - Planned allocations for raised funds include RMB 350 million for automation projects, RMB 50 million for R&D center construction, and RMB 300 million for expanding medical packaging capacity [3]. Group 5: Competitive Advantages - Hualan's competitive advantages include formulation and process technology, product quality, and brand strength [4]. - The company possesses independent research capabilities for various materials used in medical seals, which is crucial for pharmaceutical quality assurance [4].

证券代码：301093 证券简称：华兰股份 江苏华兰药用新材料股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | --- | --- | --- | |----------------------------------|-------------------------------------------------------------|------------------------------------------------------------------|-------|--------------------------|-------|-------| | | | | | | | | | 投资者关系活动类别 ☐特定对象调研 | | ☐分析师会议 | | | | | | | ☐ 媒体采访 | 业绩说明会 | | | | | | | ☐ 新闻发布会 | ☐路演活动 | | | | | | | ☐ 现场参观 | | | | | | | | ☐ 其他（请文字说明其他活动内容） | | | | | | | 形式 ☐ | 现场 网上 | ...